Source:http://linkedlifedata.com/resource/pubmed/id/11169433
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2001-2-22
|
pubmed:abstractText |
In order to analyze a putative immunomodulatory effect of NGF in experimental autoimmune encephalomyelitis (EAE) of the Lewis rat, we transduced myelin basic protein (MBP)-specific CD4(+) T cells with a recombinant retrovirus encoding NGF. These T(MBP)NGF cells secreted high levels of NGF, along with an unaltered Th1-like cytokine pattern. Transfer studies showed that T(MBP)NGF cells were unable to mediate clinical EAE, when transferred alone, and, more important, they efficiently suppressed induction of clinical EAE by non-transduced MBP-specific T cells (T(MBP )cells). In contrast, NGF transduced ovalbumin-specific T cells, which secreted high NGF levels, did not affect EAE induction. Suppression of clinical EAE by T(MBP)NGF cells was associated with a general reduction of inflammatory CNS infiltrates, with a most pronounced decrease of the monocyte/macrophage component. Using a culture model of the endothelial blood-brain barrier (BBB), we found that NGF directly acts on blood-derived monocytes via the p75 NGF receptor, thus interfering with monocyte migration through the activated BBB endothelium. Our data establish NGF as an anti-inflammatory mediator interfering with T cell mediated autoimmune disease in the CNS. They further point to monocyte migration through blood vascular endothelium as one possible mechanism of NGF action.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class II,
http://linkedlifedata.com/resource/pubmed/chemical/Nerve Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Nerve Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0014-2980
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
31
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
11-22
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11169433-Animals,
pubmed-meshheading:11169433-Cell Movement,
pubmed-meshheading:11169433-Encephalomyelitis, Autoimmune, Experimental,
pubmed-meshheading:11169433-Endothelium, Vascular,
pubmed-meshheading:11169433-Gene Therapy,
pubmed-meshheading:11169433-Histocompatibility Antigens Class II,
pubmed-meshheading:11169433-Monocytes,
pubmed-meshheading:11169433-Nerve Growth Factor,
pubmed-meshheading:11169433-Rats,
pubmed-meshheading:11169433-Rats, Inbred Lew,
pubmed-meshheading:11169433-Receptor, Nerve Growth Factor,
pubmed-meshheading:11169433-T-Lymphocytes,
pubmed-meshheading:11169433-Transfection,
pubmed-meshheading:11169433-Tumor Necrosis Factor-alpha
|
pubmed:year |
2001
|
pubmed:articleTitle |
Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration.
|
pubmed:affiliation |
Max-Planck-Institute of Neurobiology, Martinsried, Munich, Germany.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|